Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T13:43:01.152Z.
Calculation as of: 2026-10-06T13:43:01.152Z.
Quote observation: 2026-10-06T13:40:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 771dc6670e9772695969b0bf6104b917a4d7f40f340cdb77ec2424dd20cacd43
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Inhibrx Biosciences Inc.
Market Cap
$1.40B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.40B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.38B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.43B
Operating Cash Flow Yield
1.26%
TTM Avg
0.67%
3Y Avg
0.67%
5Y Avg
1.44%
Market Cap
$1.36B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.47B
Operating Cash Flow Yield
10.69%
TTM Avg
10.55%
3Y Avg
6.87%
5Y Avg
5.24%
Market Cap
$1.45B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.33B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Inhibrx Biosciences Inc. (INBX) | $1.40B | N/A | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.40B | N/A | N/A | N/A | N/A |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.38B | N/A | N/A | N/A | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.43B | 1.26% | 0.67% | 0.67% | 1.44% |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.36B | N/A | N/A | N/A | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.47B | 10.69% | 10.55% | 6.87% | 5.24% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.45B | N/A | N/A | N/A | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $1.33B | N/A | N/A | N/A | N/A |
| GH Research PLC (GHRS)vs › | $1.51B | N/A | N/A | N/A | N/A |
| Kardigan, Inc. (KARD)vs › | $1.29B | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
